Harvard Business Review

SEPTEMBER 12, 2012

The study assembles considerable evidence about the hidden business model of major pharmaceutical companies: to devote most of their research budget to developing hundreds of drugs that provide few if any advantages over existing drugs and then market them heavily to doctors and patients. See The Risks of Prescription Drugs (Columbia 2010).

Business Model 15

Business Model Company Pharmaceuticals Price 15

Harvard Business Review

DECEMBER 6, 2012

For example, the SEC in 2010 had charged Goldman with misleading some of the parties to a billion dollar transaction (involving a complex derivative called a synthetic collateralized debt obligation), alleging specific facts about undisclosed conflicts of interest. Goldman settled within months for $550 million.

Conflict of Interest 8

Conflict of Interest CEO Asset Management Committee 8

Harvard Business Review

FEBRUARY 3, 2017

By that I mean that pharma companies should develop innovative treatments for pervasive unmet medical needs; avoid corruption, collusion, and other unethical marketing practices; and make sure that their products reach as many patients around the world as possible. For instance, 60 institutional investors, collectively managing more than $5.5

Reputation 8

Reputation Pharmaceuticals Price Business Model 8